• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

阿哌沙班成功治疗一名需要血液透析的慢性肾病患者的肝素诱导的血小板减少症。

Successful treatment of heparin-induced thrombocytopenia with apixaban in a patient with chronic kidney disease requiring hemodialysis.

作者信息

Trujillo Agudelo Daniela, Ramirez Quintero Juan D, Arango Barrientos Marcos

机构信息

Internal Medicine Universidad Pontificia Bolivariana Medellin Colombia.

Internal Medicine Hospital Pablo Tobón Uribe Medellin Colombia.

出版信息

Clin Case Rep. 2018 Sep 25;6(11):2147-2149. doi: 10.1002/ccr3.1817. eCollection 2018 Nov.

DOI:10.1002/ccr3.1817
PMID:30455909
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6230604/
Abstract

Heparin-induced thrombocytopenia (HIT) is a prothrombotic state that can affect patients with chronic kidney disease (CKD) on hemodialysis (HD). This case highlights the potential usefulness of apixaban therapy for patients with HIT and CKD on HD.

摘要

肝素诱导的血小板减少症（HIT）是一种促血栓形成状态，可影响接受血液透析（HD）的慢性肾脏病（CKD）患者。本病例突出了阿哌沙班治疗对HD上患有HIT和CKD的患者的潜在效用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a0f/6230604/5542529e486e/CCR3-6-2147-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a0f/6230604/5542529e486e/CCR3-6-2147-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a0f/6230604/5542529e486e/CCR3-6-2147-g001.jpg

相似文献

1
Successful treatment of heparin-induced thrombocytopenia with apixaban in a patient with chronic kidney disease requiring hemodialysis.阿哌沙班成功治疗一名需要血液透析的慢性肾病患者的肝素诱导的血小板减少症。
Clin Case Rep. 2018 Sep 25;6(11):2147-2149. doi: 10.1002/ccr3.1817. eCollection 2018 Nov.
2
An Open-Label, Single-Arm, Pilot Intervention Study to Assess the Efficacy and Safety of Apixaban in Heparin-Induced Thrombocytopenia.阿哌沙班治疗肝素诱导血小板减少症的开放性、单臂、初步干预研究的疗效和安全性评估。
J Clin Pharmacol. 2022 Nov;62(11):1379-1384. doi: 10.1002/jcph.2096. Epub 2022 Jun 25.
3
[Apixaban as therapeutic option in nephropathy patients with heparin-induced thrombocytopenia (HIT)].阿哌沙班作为肝素诱导的血小板减少症（HIT）肾病患者的治疗选择
Gac Med Mex. 2015 Nov-Dec;151(6):798-801.
4
Heparin-Induced Thrombocytopenia in Chronic Hemodialysis Patients.慢性血液透析患者肝素诱导的血小板减少症。
Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231177993. doi: 10.1177/10760296231177993.
5
[Patient who developed heparin-induced thrombocytopenia type II after 24 years on hemodialysis].[在接受血液透析24年后发生II型肝素诱导的血小板减少症的患者]
Acta Med Croatica. 2012 Oct;66 Suppl 2:68-71.
6
Prevalence of heparin-induced antibodies in patients with chronic renal failure undergoing hemodialysis.接受血液透析的慢性肾衰竭患者中肝素诱导抗体的患病率。
J Clin Lab Anal. 2005;19(5):189-95. doi: 10.1002/jcla.20076.
7
Pseudo-pulmonary embolism as a sign of acute heparin-induced thrombocytopenia in hemodialysis patients: safety of resuming heparin after disappearance of HIT antibodies.假性肺栓塞作为血液透析患者急性肝素诱导的血小板减少症的一种表现：肝素诱导的血小板减少症（HIT）抗体消失后重新使用肝素的安全性
Nephron Clin Pract. 2006;104(4):c143-8. doi: 10.1159/000094959. Epub 2006 Aug 10.
8
Evaluation of circuit and AV fistula clotting and detection of anti-PF4/heparin complex antibodies in hemodialysis patients suspected of having heparin-induced thrombocytopenia.评估血液透析患者的电路和动静脉瘘血栓形成，并检测疑似肝素诱导的血小板减少症患者的抗 PF4/肝素复合物抗体。
Clin Appl Thromb Hemost. 2013 Jan-Feb;19(1):73-8. doi: 10.1177/1076029612436676. Epub 2012 Feb 16.
9
Rivaroxaban and apixaban for the treatment of suspected or confirmed heparin-induced thrombocytopenia.利伐沙班和阿哌沙班用于治疗疑似或确诊的肝素诱导的血小板减少症。
J Clin Pharm Ther. 2022 Jan;47(1):112-118. doi: 10.1111/jcpt.13537. Epub 2021 Oct 26.
10
Novel fondaparinux protocol for anticoagulation therapy in adults with renal failure and suspected heparin-induced thrombocytopenia: a retrospective review of institutional protocol.新型磺达肝素钠抗凝方案在肾衰竭伴疑似肝素诱导血小板减少症成人患者中的应用：对机构方案的回顾性研究。
BMC Pharmacol Toxicol. 2023 Jan 13;24(1):2. doi: 10.1186/s40360-023-00643-4.

引用本文的文献

1
Management of heparin-induced thrombocytopenia: systematic reviews and meta-analyses.肝素诱导的血小板减少症的管理：系统评价与荟萃分析
Blood Adv. 2020 Oct 27;4(20):5184-5193. doi: 10.1182/bloodadvances.2020002963.
2
Apixaban: a novel agent to treat heparin induced thrombocytopenia and to prevent embolism in patient with atrial fibrillation after multiple valve replacement?阿哌沙班：新型药物可治疗肝素诱导的血小板减少症，并预防多次瓣膜置换术后心房颤动患者的栓塞？
J Thromb Thrombolysis. 2019 Nov;48(4):619-622. doi: 10.1007/s11239-019-01910-0.

本文引用的文献

1
Evaluation of bleeding in patients receiving direct oral anticoagulants.接受直接口服抗凝剂治疗患者的出血情况评估。
Vasc Health Risk Manag. 2017 Aug 23;13:325-342. doi: 10.2147/VHRM.S121661. eCollection 2017.
2
Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review.直接口服抗凝剂治疗 HIT：汉密尔顿经验更新及文献回顾。
Blood. 2017 Aug 31;130(9):1104-1113. doi: 10.1182/blood-2017-04-778993. Epub 2017 Jun 23.
3
Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients.血液透析患者阿哌沙班稳态时的药代动力学
J Am Soc Nephrol. 2017 Jul;28(7):2241-2248. doi: 10.1681/ASN.2016090980. Epub 2017 Mar 16.
4
CLINICAL PRACTICE. Heparin-Induced Thrombocytopenia.临床实践。肝素诱导的血小板减少症。
N Engl J Med. 2015 Jul 16;373(3):252-61. doi: 10.1056/NEJMcp1411910.
5
Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.肝素诱导的血小板减少症的治疗和预防：抗血栓治疗与血栓预防，第 9 版：美国胸科医师学会基于证据的临床实践指南。
Chest. 2012 Feb;141(2 Suppl):e495S-e530S. doi: 10.1378/chest.11-2303.